Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Triple Negative Breast Cancer|Hormone Receptor Positive Tumor
Interventions: DRUG: Talazoparib|DRUG: ASTX727
Sponsor: Kathy Miller
Collaborators: Pfizer|Astex Pharmaceuticals, Inc.|Van Andel Institute Stand Up to Cancer Team